Overview on the efficacy and safety of gadobutrol: An MRI contrast agent for the CNS, body and vessels

Juan E. Gutierrez, Sara Koenig, Josy Breuer

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Contrast-enhanced MRI has become a mainstay of clinical imaging with unlimited applications. However, a limitation of conventional contrast agents in MRI is the insufficient signal-to-noise ratios due to relaxivity. Gadobutrol (1.0 mmol/ml), an extracellular macrocyclic contrast agent of high stability, is indicated for contrast-enhanced MRI of adults, adolescents and children 2 years of age and older. Gadobutrol offers increased T 1 relaxivity, which improves MR image quality and clinical use of the technique.

Original languageEnglish (US)
Pages (from-to)25-40
Number of pages16
JournalImaging in Medicine
Volume4
Issue number1
DOIs
StatePublished - Feb 1 2012

Keywords

  • CNS
  • Gadavist™
  • Gadovist™
  • contrast-enhanced MRA
  • contrast-enhanced MRI
  • gadobutrol
  • gadolinium-based contrast agent
  • kidney
  • liver

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Overview on the efficacy and safety of gadobutrol: An MRI contrast agent for the CNS, body and vessels'. Together they form a unique fingerprint.

Cite this